|
Any content you receive is for information purposes only. Always conduct your own research.
*Sponsored
VolitionRx Limited (NYSE AMERICAN: VNRX) Just Landed At The Top Of The
Our Watchlist For Tomorrow Morning—Tuesday, November 17, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly
To Your Phone. Up To 10X Faster Than Email.
Take A Closer Look At (VNRX) Before Tomorrow Morning…
November 16, 2026
Dear Reader,
Today’s profile made an approx. 27% move off from Friday’s range — and now we’re shifting our focus to what’s lining up for tomorrow morning…
The best names in diagnostics rarely announce themselves with a press conference…
They build quietly.
They publish peer-reviewed data.
They sign collaboration agreements with companies whose market caps dwarf their own.
And then, one quarter at a time, revenue starts doubling.
That last part just got confirmed — again.
VolitionRx Limited (NYSE AMERICAN: VNRX) reported Q3 2026 results last week showing revenue of approximately $1.6M for the quarter — up 157% year-over-year.
That’s an acceleration from the 112% growth the company posted in the first half.
And Q3 alone exceeded the company’s entire first-half revenue of $1.4M.
Meanwhile, operating expenses dropped 14%. The operating loss narrowed by 35%. And the company fully prepaid its $7.5M convertible note in cash during the quarter.
CEO Cameron Reynolds voluntarily cut his own salary to 50% of its original level — effective November 1 — until a substantial licensing agreement is executed.
The full board followed with cuts of at least 50%.
That’s not a team coasting…
That’s a team that believes something material is around the corner.
VolitionRx Limited (NYSE AMERICAN: VNRX) is a multi-national epigenetics company developing simple, cost-effective blood tests designed to detect cancer, sepsis, and other life-threatening conditions far earlier than current methods allow.
Its Nu.Q® NETs sepsis assay has been selected as the sole biomarker in a €6.3M government-backed clinical program in France.
In October, the company signed a letter of intent with MissionPharma — a global healthcare distributor reaching more than 100M patients annually — to explore launching a finger-prick sepsis test in humanitarian settings worldwide.
And it’s in active licensing discussions with more than a dozen of the world’s leading diagnostic companies across addressable markets the company now estimates at over $36B.
For a company with a market cap below $8M according to Yahoo Finance, the disconnect between what’s being built and what the market currently reflects is worth a closer look.
VolitionRx Limited (NYSE AMERICAN: VNRX) will be topping our watchlist tomorrow morning — Tuesday, November 17, 2026.

According to Yahoo Finance, (NYSE AMERICAN: VNRX) has a float less than 13M listed as available to the public—with a float that small, the potential exists for big moves if demand begins to shift.
Several analysts have targets on (VNRX) that suggest significant upside potential from its recent $.18 range.
Justin Walsh at Jones has a $24 target.
And Michael Okunewitch at Maxim Group maintains a bullish rating with a $2 target.
What Volition Actually Does — And Why It's Different
VolitionRx Limited (NYSE AMERICAN: VNRX) isn't trying to build one test for one disease…
The company has developed a proprietary platform called Nucleosomics™ that detects characteristic epigenetic changes in nucleosomes — the structures that package DNA inside every cell — from the earliest stages of disease.
Think of it this way…
Most diagnostic approaches look for the disease itself — a tumor marker, a bacterial signature, a genetic mutation.
Volition's approach is different because it looks at what the body is already doing in response to disease, specifically how chromatin and nucleosome structures change when cells are under stress or turning malignant.
That distinction matters because it means the platform isn't limited to one condition or one sample type…
It branches into multiple commercial pillars, each targeting a distinct and massive addressable market.
Nu.Q® NETs is a CE-marked diagnostic solution already clinically available for detecting NETosis, an immune mechanism linked to sepsis.
Nu.Q® Vet is a cancer screening blood test for dogs already available in more than 20 countries, with a feline version in development.
And Capture-Seq™ is a novel liquid biopsy method that detected over 95% of Stage I and Stage II cancers in a blinded validation cohort — with clinical data now peer-reviewed and published as of August 2026.
What makes this story compelling is the range…
One platform, several clinical and commercial applications, and total addressable markets the company estimates at $36B+ on an annualized basis.

That's not a single-product company chasing a single endpoint.
That's an epigenetics platform with multiple shots on goal across human diagnostics, veterinary care, and next-generation liquid biopsy — each at a different stage of commercialization, and each capable of generating revenue independently.
A Government-Backed Sepsis Program and Global Licensing Momentum
Sepsis remains one of the deadliest conditions on the planet — responsible for an estimated 21M deaths per year worldwide.
Every hour saved in identification can have a direct impact on survival.
That's exactly what the DETECSEPS program aims to address…
Initiated by the IHU Sepsis and backed by the French government under the France 2030 plan, DETECSEPS brings together the AP-HP, Hospices Civils de Lyon, IDS France, and Volition to evaluate whether Volition's Nu.Q® NETs H3.1 biomarker, combined with clinical scoring, can identify at-risk patients the moment they arrive at the emergency department.

The program will evaluate this approach in 1,000 patients in real-world care settings — not in a controlled lab, not in a narrow sub-population, but in actual emergency rooms across multiple French hospital systems.
Cameron Reynolds, Volition’s CEO, called the selection “an exceptional vote of confidence in our Nu.Q® NETs platform”.
The clinical evidence continues to mount alongside it…
In August, Critical Care Medicine published data showing Nu.Q® NETs H3.1 is an independent predictor of 28-day mortality and need for renal replacement therapy in sepsis patients.
That confidence extends beyond France.
Beyond sepsis, VolitionRx Limited (NYSE AMERICAN: VNRX) has also successfully transferred its Nu.Q® NETs assay onto Sysmex Corporation’s platform — a diagnostic giant listed on the Tokyo Exchange with a market cap north of $20B — in preparation for what the company describes as an anticipated broader agreement. The company is also collaborating with Werfen’s Immunoassay Technology Center across NETs-related indications.
The significance of that relationship is hard to overstate.
Sysmex is one of the world's largest hematology and diagnostic automation companies, with distribution networks spanning over 190 countries and a footprint that reaches virtually every major hospital system on earth.
A formal agreement with a partner of that scale could transform Volition's commercial reach virtually overnight — taking what is currently a clinical-stage relationship and converting it into a global distribution channel backed by existing infrastructure.
And there's more…
The company confirmed active discussions with more than a dozen global diagnostic and liquid biopsy leaders, including ongoing technical evaluations.
The stated goal is to enter licensing agreements that generate upfront milestone payments, royalties, and recurring revenue — effectively letting larger companies with global infrastructure bring Volition's platform to market at scale.
That's a capital-efficient model worth paying attention to.
Rather than building out a massive direct sales force, Volition appears to be positioning itself as a platform licensor — the company that develops and validates the science, while established diagnostic giants handle manufacturing, distribution, and market access.
Potential Catalysts Stacking Up
Several near-term developments could reshape the trajectory for (VNRX)…
The company submitted a clinical manuscript in May for its Nu.Q® Vet feline cancer test, which detected 86% of feline lymphomas at 97% specificity. Peer-reviewed publication is expected this quarter.
That publication is expected to unlock a $5M contractual milestone payment — a figure that is material relative to the company’s current market cap.
The company also plans a formal conditional reimbursement submission in France for Nu.Q® Cancer in lung cancer this quarter — a potential gateway to routine clinical use in Europe.
If approved, reimbursement would mean that clinicians across the French healthcare system could order Volition's lung cancer test with costs covered by the national health program.
That kind of regulatory milestone doesn't just validate the science…
It opens a commercial channel that recurring revenue can flow through for years.
Meanwhile, the lateral flow finger-prick prototype for nucleosome detection has shown correlation with the established CE-marked Nu.Q® NETs assay in confirmed sepsis patients.
If that prototype reaches commercial form, it could function like a rapid home test — similar to CV-era testing — and dramatically expand the addressable market for sepsis detection beyond centralized labs.
The implications of that are enormous…
A finger-prick test for sepsis risk could be deployed in ambulances, rural clinics, battlefield triage, and nursing homes — anywhere a lab instrument can't go but early detection still matters.
That’s the kind of product evolution that turns a niche diagnostic into a household-level screening tool.
And there’s now a potential partner to help get it there…
Last month, Volition signed a letter of intent with MissionPharma A/S — a Danish healthcare distributor owned by Toyota Tsusho Corporation that supplies UN agencies, the WHO, and ministries of health, reaching more than 100M patients annually — to explore developing and launching the finger-prick test for neonatal sepsis detection in humanitarian and resource-constrained settings worldwide.
The combined pipeline begins to look like something much larger than any single assay — it looks like a platform company with the potential to redefine how and when disease is found.
Analysts covering (VNRX) reflect the forward-looking nature of this setup…
The consensus among several covering analysts is a bullish rating, with an average target of $13.62.
Justin Walsh at Jones has a $24 target.
And Michael Okunewitch at Maxim Group maintains a bullish momentum rating with a $2 target.

7 Reasons Why We’ll Be Taking A Closer Look At (VNRX) Tomorrow Morning
— Tuesday, November 17, 2026
1. Analyst Coverage: several analysts covering (VNRX) maintain bullish ratings, with published targets ranging from $2 to as high as $24.
2. Small Float: with fewer than 13M shares listed in the public float, (VNRX) could react sharply if demand begins to build.
3. Revenue Surge: Q3 revenue reached about $1.6M, up 157% year over year for (VNRX) and above its entire first-half revenue of $1.4M.
4. Lower Expenses: operating expenses fell 14% while the operating loss narrowed 35% for (VNRX) during Q3.
5. Sepsis Validation: a 1,000-patient French government-backed program selected Nu.Q® NETs from (VNRX) as the biomarker being evaluated in real-world emergency care.
6. Global Partnerships: active discussions with more than a dozen diagnostic and liquid biopsy leaders give (VNRX) multiple potential licensing pathways.
7. Cancer Detection: Capture-Seq™ from (VNRX) detected over 95% of Stage I and Stage II cancers in a blinded validation cohort.
Take A Closer Look At (VNRX) Before Tomorrow Morning…

This is a name that has built something real across multiple verticals — sepsis, cancer detection, veterinary diagnostics — and the catalysts aren’t theoretical anymore. They’re arriving.
Revenue up 157% in Q3. The $7.5M convertible note fully prepaid. A CEO who cut his own salary in half until a licensing deal closes. And a pipeline of near-term catalysts — the feline milestone, the French reimbursement submission, the MissionPharma partnership, and discussions with more than a dozen global diagnostic leaders — all lining up over the coming weeks.
VolitionRx Limited (NYSE AMERICAN: VNRX) deserves a closer look tomorrow morning.
Check it out before you shut down for the night. Also, keep an eye out for the next update, it could be coming before Tuesday’s bell.
Sincerely,
Jeff Ackerman
Managing Editor
Stock News Trends
StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and SNT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between TD Media LLC and Goldwyn Media LLC, TD Media LLC has been hired for a period beginning on 11/16/2026 and ending on 11/17/2026 to publicly disseminate information about (VNRX:US) via digital communications. Under this agreement, Goldwyn Media LLC has paid TD Media LLC fifty thousand USD (“Funds”). To date, including under the previously described agreement, TD Media LLC has been paid eight hundred fifteen thousand five hundred USD (“Funds”). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither TD Media LLC and their member own shares of (VNRX:US).
Please see important disclosure information here: https://lifewatermedia.com/disclosure/vnrx-RNuQF/#details
|
No comments:
Post a Comment